secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001558370-25-010415
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia extends Phase 1 DA-1726 48mg MAD cohort to 8 weeks; top-line data Q4 2025
--------------------------------------------------------------------------------

- Extended 48 mg MAD cohort to 8 weeks from 4; first patient received fifth weekly dose.
- Top-line data from the extended cohort expected in Q4 2025.
- Prior 32 mg dose data: mean weight loss 4.3% by Day 26, early satiety in 83% of patients.
- Waist circumference reduction of up to 3.9 inches by Day 33 at 32 mg dose.
- DA-1726 is a dual GLP1R/GCGR agonist for obesity with a 3:1 balanced activation ratio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/0001558370-25-010415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/mtva-20250806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer